<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02168426</url>
  </required_header>
  <id_info>
    <org_study_id>GDIRB2013-15</org_study_id>
    <nct_id>NCT02168426</nct_id>
  </id_info>
  <brief_title>Randomized Control Trial on Seprafilm and Guardix in Preventing Ileus</brief_title>
  <official_title>Randomized Control Trial on Seprafilm and Guardix in Preventing Ileus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gachon University Gil Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy of Seprafilm and guardix in reducing the
      incidence of bowel obstruction and to evaluate the incidence of all serious adverse events
      (SAEs) associated with the use of Seprafilm and guardix occurring within 30 days
      postoperatively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ileus rate</measure>
    <time_frame>within 60 days</time_frame>
    <description>Reducing the incidence of bowel obstruction following intestinal resection, and subsequently, reducing the number of re-operations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse effect rate</measure>
    <time_frame>within 60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Patient Under Going Colorectal and Stomach Cancer Surgery</condition>
  <arm_group>
    <arm_group_label>Guardix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6g per body</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seprafilm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 sheet per body</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Guardix</intervention_name>
    <description>Applying 6g of guardix during abdominal surgery</description>
    <arm_group_label>Guardix</arm_group_label>
    <arm_group_label>Seprafilm</arm_group_label>
    <other_name>Guardix, Sami pharmaceutical company</other_name>
    <other_name>Seprafilm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Seprafilm</intervention_name>
    <description>Applying 1 sheet of seprafilm during abdominal surgery</description>
    <arm_group_label>Guardix</arm_group_label>
    <arm_group_label>Seprafilm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of GI cancer

          -  Operable

        Exclusion Criteria:

          -  Withdrew consent

          -  Pregnant

          -  Ascites

          -  Distant metastasis

          -  Liver dysfunction (serum total bilirubin &gt;2.0 mg/dL)

          -  Renal failure (serum creatinine &gt;1.5 mg/dL)

          -  A past history of small bowel obstruction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Won-Suk Lee</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2014</study_first_submitted>
  <study_first_submitted_qc>June 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2014</study_first_posted>
  <last_update_submitted>August 28, 2015</last_update_submitted>
  <last_update_submitted_qc>August 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gachon University Gil Medical Center</investigator_affiliation>
    <investigator_full_name>Won-Suk Lee</investigator_full_name>
    <investigator_title>Won-Suk Lee</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

